Matthew J Naylor
Overview
Explore the profile of Matthew J Naylor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1102
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tan K, Naylor M
Front Oncol
. 2022 Jun;
12:876451.
PMID: 35646658
Breast cancer is a complex, dynamic disease that acquires heterogeneity through various mechanisms, allowing cancer cells to proliferate, survive and metastasise. Heterogeneity is introduced early, through the accumulation of germline...
2.
Xie K, Tan K, Naylor M
Front Oncol
. 2022 May;
12:854151.
PMID: 35547880
Prostate cancer is the second most diagnosed cancer among men worldwide. Androgen deprivation therapy, the most common targeted therapeutic option, is circumvented as prostate cancer progresses from androgen dependent to...
3.
Tan K, Naylor M
Front Physiol
. 2022 Mar;
13:840826.
PMID: 35330933
Breast and prostate cancers are among the most commonly diagnosed cancers worldwide, and together represented almost 20% of all new cancer diagnoses in 2020. For both cancers, the primary treatment...
4.
Teo W, Holliday H, Karthikeyan N, Cazet A, Roden D, Harvey K, et al.
Front Cell Dev Biol
. 2020 Aug;
8:552.
PMID: 32766238
Breast cancers display phenotypic and functional heterogeneity and several lines of evidence support the existence of cancer stem cells (CSCs) in certain breast cancers, a minor population of cells capable...
5.
Baker L, Holliday H, Roden D, Krisp C, Wu S, Junankar S, et al.
Breast Cancer Res
. 2020 Jun;
22(1):63.
PMID: 32527287
Background: Basal-like breast cancer (BLBC) is a poorly characterised, heterogeneous disease. Patients are diagnosed with aggressive, high-grade tumours and often relapse with chemotherapy resistance. Detailed understanding of the molecular underpinnings...
6.
Piggin C, Roden D, Law A, Molloy M, Krisp C, Swarbrick A, et al.
PLoS Genet
. 2020 Jan;
16(1):e1008531.
PMID: 31895944
Acquired resistance to endocrine therapy is responsible for half of the therapeutic failures in the treatment of breast cancer. Recent findings have implicated increased expression of the ETS transcription factor...
7.
Oakes S, Gallego-Ortega D, Stanford P, Junankar S, Au W, Kikhtyak Z, et al.
PLoS Genet
. 2017 Nov;
13(11):e1007072.
PMID: 29117179
We identified a non-synonymous mutation in Oas2 (I405N), a sensor of viral double-stranded RNA, from an ENU-mutagenesis screen designed to discover new genes involved in mammary development. The mutation caused...
8.
Anderson L, Owens T, Naylor M
Biophys Rev
. 2017 May;
6(2):191-202.
PMID: 28510181
The correct control of cell fate decisions is critical for metazoan development and tissue homeostasis. It is established that the integrin family of cell surface receptors regulate cell fate by...
9.
Anderson L, Owens T, Naylor M
Biophys Rev
. 2017 May;
6(2):203-213.
PMID: 28510180
Integrins are ubiquitously expressed cell surface receptors that play a critical role in regulating the interaction between a cell and its microenvironment to control cell fate. These molecules are regulated...
10.
Naylor M
Dev Cell
. 2016 Sep;
38(5):450-1.
PMID: 27623380
Mammary epithelial phagocytosis is critical for removal of apoptotic cells during involution, but the mechanisms governing this process are largely unknown. In this issue of Developmental Cell, Akhtar et al....